AMENDMENT TO THE CLAIMS

Amendments to the claims are reflected in the following listing of claims, which replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-60 (canceled)

61. (New) A method of assessing susceptibility to myocardial infarction (MI) or stroke in a human individual, the method comprising:

screening nucleic acid of the individual to determine whether the nucleic acid comprises a 5-lipoxygenase activating protein (FLAP) haplotype that comprises polymorphisms SG13S114, allele T; SG13S32, allele A; SG13S25, allele G; and SG13S89, allele G;

wherein the presence of the haplotype in the nucleic acid of the individual identifies the individual as having elevated susceptibility to MI, and wherein the absence of the haplotype in the nucleic acid of the individual identifies the individual as not having the elevated susceptibility to MI or stroke.

62. (New) The method of claim 61, wherein the haplotype further comprises polymorphism SG13S99, allele T.

63. (New) The method of claim 61 or 62, wherein the presence of the haplotype correlates with an increased risk of MI of at least 20% in the population.

64. (New) The method of claim 61 or 62, wherein the presence of the haplotype correlates with an odds ratio of at least about 1.2 in the population.

65. (New) The method of claim 61 or 62, comprising obtaining a biological sample from the individual that comprises the nucleic acid, and screening the nucleic acid from the biological sample.

66. (New) The method of claim 61 or 62, wherein the screening step comprises subjecting said nucleic acid to at least one procedure selected from the group consisting of: (a) enzymatic amplification of nucleic acid from the individual; (b) electrophoretic analysis; (c) restriction fragment length polymorphism analysis; and (d) nucleotide sequence analysis.